Zhejiang AngLiKang Pharmaceutical CO.,LTD. Stock

Equities

002940

CNE100003GC2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-19 pm EDT 5-day change 1st Jan Change
14.87 CNY -1.13% Intraday chart for Zhejiang AngLiKang Pharmaceutical CO.,LTD. -5.47% -31.51%
Sales 2021 1.38B 190M Sales 2022 1.57B 216M Capitalization 3.68B 507M
Net income 2021 120M 16.53M Net income 2022 127M 17.49M EV / Sales 2021 1.98 x
Net cash position 2021 747M 103M Net cash position 2022 458M 63.05M EV / Sales 2022 2.06 x
P/E ratio 2021
28.6 x
P/E ratio 2022
29.1 x
Employees 981
Yield 2021
0.83%
Yield 2022
1.11%
Free-Float 51.34%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan. CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023 CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-1.13%
1 week-5.47%
Current month-14.39%
1 month-13.50%
3 months-13.45%
6 months-27.89%
Current year-31.51%
More quotes
1 week
14.73
Extreme 14.73
15.50
1 month
14.73
Extreme 14.73
18.62
Current year
11.84
Extreme 11.84
22.04
1 year
11.84
Extreme 11.84
22.59
3 years
11.84
Extreme 11.84
25.79
5 years
11.84
Extreme 11.84
33.19
10 years
11.84
Extreme 11.84
33.19
More quotes
Managers TitleAgeSince
Director of Finance/CFO 46 21-01-04
Chairman 57 14-12-08
Director/Board Member 41 21-01-04
Members of the board TitleAgeSince
Director/Board Member 55 21-01-04
Chairman 57 14-12-08
Director/Board Member 54 14-12-08
More insiders
Date Price Change Volume
24-06-20 14.87 -1.13% 992,252
24-06-19 15.04 -1.05% 960,196
24-06-18 15.2 -0.52% 1,430,075
24-06-17 15.28 -1.55% 876,603
24-06-14 15.52 -1.34% 983,861

End-of-day quote Shenzhen S.E., June 19, 2024

More quotes
Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a China-based company principally engaged in the research, development, production and sales of chemical raw materials and preparations. The Company's products mainly include cephalosporin and penicillin series, anti-hypertension series, digestive system series, kidney disease series and others.
More about the company
  1. Stock Market
  2. Equities
  3. 002940 Stock